The value of irbesartan in the management of hypertension

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 11, 2009, Pages 1817-1831

  Bramlage, Peter ^a   Durand Zaleski, Isabelle ^b   Desai, Nisha ^c   Pirk, Olaf ^d   Hacker, Caroline ^d  

^a Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^b HENRI MONDOR HOSPITAL   (France)

^c IMS Health GmbH and Co OHG ^*

^d WG Consulting   (United Kingdom)

Author keywords

Angiotensin receptor blockers; Cost; Hypertension; Irbesartan

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; NIFEDIPINE; PLACEBO; VALSARTAN;

BLOOD PRESSURE; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; MICROALBUMINURIA; PRACTICE GUIDELINE; PROTEINURIA; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES;

EID: 68149098704     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903103820     Document Type: Review

References (62)

1. WHO. Report: reducing Risks, Promoting Healthy Life. Geneva, 2002
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-2571
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187 (Pubitemid 46924065)
4. American Diabetes Association. Treatment of hypertension in adults with diabetes. Position statement. Diabetes Care 2003;26:80S-82
5. Allendar S, Scarborough P, Peto V, et al. European cardiovascular disease statistics 2008. Eur Heart Netw 2008;1-112. Available from: http://www.ehnheart.org/files/ statistics%202008%20web-161229A.pdf
6. Luengo-Fernandez R, Leal J, Gray A, et al. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92:1384-1389 (Pubitemid 44578822)
7. NICE. Management of hypertension in adults in primary care: partial update. Costing report: implementing NICE guidance in England. NICE clinical guideline no. 34. London: NICE, 2006
8. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913 (Pubitemid 35472129)
9. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-19 (Pubitemid 38293521)
10. Wilber JA, Barrow JG. Hypertension - a community problem. Am J Med 1972;52:653-663
11. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003;7:1-94
12. Matchar DB, Mccrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29
13. Larochelle P, Flack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol 1997;80:1613-1615
14. Neutel JM, Germino FW, Smith D. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2005;6:84-89 (Pubitemid 41699978)
15. Stumpe KO, Haworth D, Hoglund C, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998;7:31-37 (Pubitemid 28137524)
16. Bobrie G, Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005;18:1482-1488 (Pubitemid 41566680)
17. Mancia G, Korlipara K, van Rossum P, et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002;7:135-142 (Pubitemid 34913423)
18. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998;11:445-453 (Pubitemid 28231457)
19. Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/ hydrochlorothiazide and losartan/ hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res 2005;33:620-631 (Pubitemid 43012617)
20. Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther 1998;20:398-409 (Pubitemid 28343494)
21. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91, 318 (Pubitemid 33040384)
22. Franklin SS, Neutel JM, Donovan M, et al. Irbesartan/Hydrochlorothiazide as initial therapy: subanalysis in patients with systolic BP>180mmHg and diastolic BP ≥110 mmHg, efficacy and safety. J Hypertens 2008;26:S159
23. Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/ hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005;7:578-586
24. Schmieder RE, Krekler M. Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ. MMW Fortschr Med 2005;147(Suppl 3):97-101 (Pubitemid 41228497)
25. Strutz F, Bramlage P, Paar WD. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients. Curr Med Res Opin 2005;21:1433-1440 (Pubitemid 41368576)
26. Sharplin P, Chamberlain G, Beckham C, et al. Antihypertensive effect of Angiotensin Receptor Blockers vs. other classes of antihypertensives in UK primary care. J Am Coll Cardiol 2008;51:A336
27. Sharplin P, Chamberlain G, Beckham C, et al. An analysis of the antihypertensive effectiveness of irbesartan vs. losartan across both single and in combination with HCTZ formulations. J Hypertens 2008;26:S169-70
28. Sharplin P, et al. Chamberlain G, Beckham C. An analysis of the antihypertensive effectiveness of irbesartan vs. valsartan. J Hypertens 2008;26:S171-2
29. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-681 (Pubitemid 28421488)
30. Degli-Esposti L, Di Martino M, Saragoni S, et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens (Greenwich) 2004;6:76-84
31. Erkens JA, Panneman MM, Klungel OH. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005;14:795-803
32. Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich) 2007;9:692-700
33. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007;3:999-1005
34. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878 (Pubitemid 34940826)
35. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860 (Pubitemid 34940824)
36. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005;16:3027-3037 (Pubitemid 44743500)
37. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-549 (Pubitemid 38124675)
38. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869 (Pubitemid 34940825)
39. McIntyre H, Costa FV, Dusing R, et al. The role of losartan in cost-effective hypertension control. Curr Med Res Opin 2002;18:139-145 (Pubitemid 34665751)
40. Muszbek N, Brixner D, Benedict A, et al. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008;62:338-351
41. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998;12:533-537 (Pubitemid 28430222)
42. Risk and costs of the first hypertension-associated event, compliance and persistence in naïve hypertensive patients after initiating monotherapy. ISPOR 11th Annual European Congress. 2008
43. Australia R. Angiotensin II Receptor Antagonists: Submission to the Pharmaceutical Benefits Advisory Committee. 2004
44. Knudsen MS, Lange M, Dahl E, et al. Cost effectiveness of long term treatment of hypertension with irbesartan vs. losartan or no treatment in Denmark. Value in Health 2006;9(6):A348
45. Ekman M, Bienfait-Beuzon C, Jackson J. Cost-effectiveness of irbesartan/ hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. J Hum Hypertens 2008;22:845-855
46. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. Pharmacoeconomics 2003;21:61-74
47. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
48. Jönsson B, Carides GW, Burke TA, et al. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. J Hypertens 2005;23:1425-1431 (Pubitemid 40933965)
49. Szucs TD, Sandoz MS, Keusch GW. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland-an analysis of the RENAAL study. Swiss Med Wkly 2004;134:440-447 (Pubitemid 39221764)
50. Ratzmann KP, Pirk O, Carels J, et al. Einsparpotentiale in der Therapie hypertoner Typ-2-Diabetiker aufgrund verzögerter terminaler Niereninsuffizienz. Pharmacoeconomics - German Research Articles 2004;2:43-52
51. Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003;25:2102-2119 (Pubitemid 36936601)
52. Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004;27:1897-1903 (Pubitemid 38989229)
53. Palmer AJ, Valentine WJ, Chen R, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 2008;23:1216-1223 (Pubitemid 351767535)
54. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223 (Pubitemid 40138015)
55. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428
56. Chobanian AV. Does it matter how hypertension is controlled? N Engl J Med 2008;359:2485-2488
57. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians, September 2008
58. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530
59. Mathes J, Kostev K, Gabriel A, et al. Risks and costs of the first hypertensionassociated event, compliance and persistence in naive hypertensive patients after initiating monotherapy. Value Health 2008;11:A415, PCV108
60. Conlin PR, Gerth WC, Fox J, et al. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23:1999-2010 (Pubitemid 34073191)
61. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-575 (Pubitemid 35021364)
62. Hasford J, Schroder-Bernhardi D, Rottenkolber M, et al. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 2007;63:1055-1061 (Pubitemid 47561800)